How many stocks are there of Immutep?
The current number of stocks of Immutep is 900.69 M undefined.
Immutep Stocks 2024
Immutep Stocks
900.69 M
Ticker
IMM.AX
ISIN
AU000000IMM6
WKN
A2H81H
In 2024, Immutep had 900.69 M outstanding stocks, a 0% change from the 900.69 M stocks in the previous year.
The Immutep Stocks history
| YEAR | NUMBER OF STOCKS (undefined AUD) |
|---|---|
| 2030e | 900.69 |
| 2029e | 900.69 |
| 2028e | 900.69 |
| 2027e | 900.69 |
| 2026e | 900.69 |
| 2025e | 900.69 |
| 2024e | 900.69 |
| 2023 | 900.69 |
| 2022 | 870.34 |
| 2021 | 609.91 |
| 2020 | 407.29 |
| 2019 | 324.77 |
| 2018 | 262.62 |
| 2017 | 208.66 |
| 2016 | 225.16 |
| 2015 | 160.2 |
| 2014 | 122.84 |
| 2013 | 108.27 |
| 2012 | 104.47 |
| 2011 | 56.76 |
| 2010 | 50.3 |
| 2009 | 32.91 |
| 2008 | 25.79 |
| 2007 | 18.84 |
| 2006 | 18.53 |
| 2005 | 12.68 |
| 2004 | 6.97 |
Immutep shares outstanding AU000000IMM6 · A2H81H
The number of shares was Immutep in 2023 — This indicates how many shares 900.686 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Immutep earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Immutep's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Immutep’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immutep's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 6.97 M Aktien |
| 2005 | 12.68 M Aktien |
| 2006 | 18.53 M Aktien |
| 2007 | 18.84 M Aktien |
| 2008 | 25.79 M Aktien |
| 2009 | 32.91 M Aktien |
| 2010 | 50.3 M Aktien |
| 2011 | 56.76 M Aktien |
| 2012 | 104.47 M Aktien |
| 2013 | 108.27 M Aktien |
| 2014 | 122.84 M Aktien |
| 2015 | 160.2 M Aktien |
| 2016 | 225.16 M Aktien |
| 2017 | 208.66 M Aktien |
| 2018 | 262.62 M Aktien |
| 2019 | 324.77 M Aktien |
| 2020 | 407.29 M Aktien |
| 2021 | 609.91 M Aktien |
| 2022 | 870.34 M Aktien |
| 2023 | 900.69 M Aktien |
| 2024e | 900.69 M Aktien |
| 2025e | 900.69 M Aktien |
| 2026e | 900.69 M Aktien |
| 2027e | 900.69 M Aktien |
| 2028e | 900.69 M Aktien |
| 2029e | 900.69 M Aktien |
| 2030e | 900.69 M Aktien |
Immutep Aktienanalyse
What does Immutep do?
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field. Immutep ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Immutep's Shares Outstanding
Immutep's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Immutep’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Immutep’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Immutep’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Immutep stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Immutep are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Immutep evolved in recent years?
The number of shares of Immutep has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Immutep as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Immutep?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Immutep pay?
Over the past 12 months, Immutep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immutep is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immutep?
The current dividend yield of Immutep is .
When does Immutep pay dividends?
Immutep pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immutep?
Immutep paid dividends every year for the past 0 years.
What is the dividend of Immutep?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immutep located?
Immutep is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immutep kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immutep from 8/25/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.
When did Immutep pay the last dividend?
The last dividend was paid out on 8/25/2024.
What was the dividend of Immutep in the year 2023?
In the year 2023, Immutep distributed 0 AUD as dividends.
In which currency does Immutep pay out the dividend?
The dividends of Immutep are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immutep
Our stock analysis for Immutep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
